- Home
- MESA vs IFRX Comparison
MESA vs IFRX Comparison
Compare MESA & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MESA
- IFRX
- Stock Information
- Founded
- MESA 1982
- IFRX 2007
- Country
- MESA United States
- IFRX Germany
- Employees
- MESA N/A
- IFRX N/A
- Industry
- MESA Air Freight/Delivery Services
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- MESA Consumer Discretionary
- IFRX Health Care
- Exchange
- MESA Nasdaq
- IFRX Nasdaq
- Market Cap
- MESA 50.0M
- IFRX 53.5M
- IPO Year
- MESA 2018
- IFRX 2017
- Fundamental
- Price
- MESA $1.39
- IFRX $1.18
- Analyst Decision
- MESA
- IFRX Strong Buy
- Analyst Count
- MESA 0
- IFRX 5
- Target Price
- MESA N/A
- IFRX $7.40
- AVG Volume (30 Days)
- MESA 116.2K
- IFRX 1.0M
- Earning Date
- MESA 11-13-2025
- IFRX 11-07-2025
- Dividend Yield
- MESA N/A
- IFRX N/A
- EPS Growth
- MESA N/A
- IFRX N/A
- EPS
- MESA N/A
- IFRX N/A
- Revenue
- MESA $406,021,000.00
- IFRX $191,224.00
- Revenue This Year
- MESA $39.81
- IFRX N/A
- Revenue Next Year
- MESA N/A
- IFRX $1,216.24
- P/E Ratio
- MESA N/A
- IFRX N/A
- Revenue Growth
- MESA N/A
- IFRX 54.36
- 52 Week Low
- MESA $0.68
- IFRX $0.71
- 52 Week High
- MESA $1.43
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- MESA 66.18
- IFRX 47.44
- Support Level
- MESA $1.34
- IFRX $1.09
- Resistance Level
- MESA $1.42
- IFRX $1.77
- Average True Range (ATR)
- MESA 0.08
- IFRX 0.21
- MACD
- MESA 0.00
- IFRX -0.05
- Stochastic Oscillator
- MESA 88.89
- IFRX 24.26
About MESA Mesa Air Group Inc.
Mesa Air Group Inc is a regional air carrier providing scheduled passenger service. It provides services to the District of Columbia, Canada, Cuba, and Mexico, and cargo services out of Cincinnati/Northern Kentucky International Airport. Flights are operated as American Eagle, United Express, or DHL Express flights to the terms of capacity purchase agreements with American and United and a flight services agreement with DHL. The business has a presence in domestic hubs and cities, including Dallas, Houston, Phoenix, and Washington-Dulles, and other regions.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.